IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
ApexOnco Front Page
Recent articles
Daraxonrasib scores a plenary session late-breaker.
First-in-human results prompt a biomarker-defined approach for CID-078.
AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
A son of glembatumumab vedotin has just started its phase 1 study.
The company will start its confirmatory bexobrutideg study in June.
Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.
Lilly buys the dual-payload ADC specialist before it’s dosed a single patient.
